Xi'An Xintong Pharmaceutical Research Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2000-05-30
- Employees
- -
- Market Cap
- -
- Website
- http://www.xtyw.com.cn
Safety, Tolerability Phase Ia Study of XT1061 in Single and Multiple Doses in Healthy Subjects
Phase 1
Recruiting
- Conditions
- Chronic Hepatitis b
- Interventions
- Drug: Test drug XT1061 capsules and placebo,Single dose groupDrug: Test drug XT1061 capsules and placebo，Food Impact GroupDrug: Test drug XT1061 capsules and placebo，Multiple dosing group
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
- Target Recruit Count
- 128
- Registration Number
- NCT06280534
- Locations
- 🇨🇳
The First Hospital of Jilin University, Jilin, Changchun, China
MB07133 for the Treatment of Patients With Unresectable Hepatocellular Carcinoma
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
- Target Recruit Count
- 91
- Registration Number
- NCT06141096
- Locations
- 🇨🇳
Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China
Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma
Phase 1
Recruiting
- Conditions
- EfficacySafety IssuesMTD
- Interventions
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT06141109
- Locations
- 🇨🇳
The First Hospital of Jilin University, Jilin, Changchun, China
A Phase Ic/IIb Study to Evaluate the Efficacy，Safety and Pharmacokinetics of HST in Patients With CHB
Phase 1
Recruiting
- Conditions
- SafetyEfficacyPharmacokinetics
- Interventions
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06122454
- Locations
- 🇨🇳
The First Hospital of Jilin University, Jilin, Changchun, China
Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study
Phase 3
Recruiting
- Conditions
- Chronic Hepatitis b
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
- Target Recruit Count
- 900
- Registration Number
- NCT04543565
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
A Study to Investigate the Safety, Tolerability, Pharmacokinetics of Single and Multiple Doses of Hepenofovir Fumarate Tablets in Healthy Volunteers.
Phase 1
- Conditions
- Chronic Hepatitis b
- Interventions
- Drug: PlaceboDrug: Hepenofovir Fumarate Tablets Single DoseDrug: Hepenofovir Fumarate Tablets Dose4
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
- Target Recruit Count
- 69
- Registration Number
- NCT04277897
© Copyright 2025. All Rights Reserved by MedPath